Covered recipient · General Payments record
PRASHANT KANU PATEL
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,668.04
- Reported across 179 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $307.41 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $121.81 | 6 |
| Acerta Pharma LLC | $33.81 | 1 |
| Lilly USA, LLC | $30.43 | 2 |
| SANOFI-AVENTIS U.S. LLC | $25.06 | 1 |
| ABBVIE INC. | $19.10 | 1 |
| E.R. Squibb & Sons, L.L.C. | $17.09 | 1 |
| Abbott Laboratories | $16.77 | 1 |
| PFIZER INC. | $15.04 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.03 | 1 |
| Amgen Inc. | $13.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $16.77 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125371502 | CMS |
| ABBVIE INC. | $19.10 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105199098 | CMS |
| Amgen Inc. | $13.27 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117650052 | CMS |
| AstraZeneca Pharmaceuticals LP | $33.81 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104353766 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.03 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118261839 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.09 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101518664 | CMS |
| Lilly USA, LLC | $16.41 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135321257 | CMS |
| Lilly USA, LLC | $14.02 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135327271 | CMS |
| Novo Nordisk Inc | $20.11 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097374457 | CMS |
| Novo Nordisk Inc | $17.68 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097822382 | CMS |
| Novo Nordisk Inc | $19.37 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096606345 | CMS |
| Novo Nordisk Inc | $23.89 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096988156 | CMS |
| Novo Nordisk Inc | $17.43 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097367698 | CMS |
| Novo Nordisk Inc | $23.33 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097822511 | CMS |
| PFIZER INC. | $15.04 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131225870 | CMS |
| SANOFI-AVENTIS U.S. LLC | $25.06 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139656336 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.